TerminatedPhase 2NCT03942211

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag

Studying Sarcoidosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Actelion
Principal Investigator: Rainer Zimmermann
Actelion
Intervention: Selexipag(drug)
Enrollment: 10 target
Eligibility: 18-75 years · All sexes
Timeline: 2021 – 2023

Study locations (30)

St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States
LSU Health Sciences Center New Orleans, New Orleans, Louisiana, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Duke University Medical Center, Durham, North Carolina, United States
University of Cincinnati, Cincinnati, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
Medical University of South Carolina (MUSC) - College of Medicine (COM), Charleston, South Carolina, United States
Universitaire Ziekenhuizen Leuven, Leuven, Belgium
Secretaria da Saude do Estado do Ceara - Hospital Doutor Carlos Alberto Studart Gomes, Fortaleza, Brazil
Hospital das Clinicas de Porto Alegre, Porto Alegre, Brazil
Hospital Das Clinicas Da Faculdade De Medicina Da USP, São Paulo, Brazil
London Health Sciences Centre, London, Ontario, Canada
Jewish General Hospital, Montreal, Quebec, Canada
Hôpital Avicenne, Bobigny, France
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03942211 on ClinicalTrials.gov

Other trials for Sarcoidosis

Additional recruiting or active studies for the same condition.

See all trials for Sarcoidosis →

← Back to all trials